|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Brahmer J, Reckamp KL, Baas P, Crino L,
Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE,
Holgado E, et al: Nivolumab versus docetaxel in advanced
squamous-cell non-small-cell lung cancer. N Engl J Med.
373:123–135. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Borghaei H, Paz-Ares L, Horn L, Spigel DR,
Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, et al:
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell
lung cancer. N Engl J Med. 373:1627–1639. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Herbst RS, Baas P, Kim DW, Felip E,
Pérez-Gracia JL, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ, et al:
Pembrolizumab versus docetaxel for previously treated,
PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010):
A randomised controlled trial. Lancet. 387:1540–1550. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Topalian SL, Hodi FS, Brahmer JR,
Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD,
Sosman JA, Atkins MB, et al: Safety, activity, and immune
correlates of anti-PD-1 antibody in cancer. N Engl J Med.
366:2443–2454. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Borghaei H BJ, Horn L, Ready N, Steins M,
Felip E, Paz-Ares L, Xx X, Barlesi F, Antonia S and Fayette J:
P2.35: nivolumab vs docetaxel in advanced NSCLC: CheckMate 017/057
2-Y update and exploratory cytokine profile analysis. Track:
Immunotherapy J Thorac Oncol. 11:S237–S238. 2016.
|
|
8
|
Sharma P, Retz M, Siefker-Radtke A, Baron
A, Necchi A, Bedke J, Plimack ER, Vaena D, Grimm MO, Bracarda S, et
al: Nivolumab in metastatic urothelial carcinoma after platinum
therapy (CheckMate 275): A multicentre, single-arm, phase 2 trial.
Lancet Oncol. 18:312–322. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhang M, Li G and Wang Y and Wang Y, Zhao
S, Haihong P, Zhao H and Wang Y: PD-L1 expression in lung cancer
and its correlation with driver mutations: A meta-analysis. Sci
Rep. 7:102552017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Goodman AM, Kato S, Bazhenova L, Patel SP,
Frampton GM, Miller V, Stephens PJ, Daniels GA and Kurzrock R:
Tumor mutational burden as an independent predictor of response to
immunotherapy in diverse cancers. Mol Cancer Ther. 16:2598–2608.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Carbone DP, Reck M, Paz-Ares L, Creelan B,
Horn L, Steins M, Felip E, van den Heuvel MM, Ciuleanu TE, Badin F,
et al: First-line nivolumab in stage IV or recurrent non-small-cell
lung cancer. N Engl J Med. 376:2415–2426. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yu Y, Zeng D, Ou Q, Liu S, Li A, Chen Y,
Lin D, Gao Q, Zhou H, Liao W and Yao H: Association of survival and
immune-related Biomarkers with immunotherapy in patients with
non-small cell lung cancer. A meta-analysis and individual
patient-level analysis. JAMA Netw Open. 2:e1968792019. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kitamura T, Qian BZ and Pollard JW: Immune
cell promotion of metastasis. Nat Rev Immunol. 15:73–86. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Tumeh PC, Harview CL, Yearley JH, Shintaku
IP, Taylor EJ, Robert L, Chmielowski B, Spasic M, Henry G, Ciobanu
V, et al: PD-1 blockade induces responses by inhibiting adaptive
immune resistance. Nature. 515:568–571. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Geng Y, Shao Y, He W, Hu W, Xu Y, Chen J,
Wu C and Jiang J: Prognostic role of tumor-infiltrating lymphocytes
in lung cancer: A meta-analysis. Cell Physiol Biochem.
37:1560–1571. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Fridman WH, Pages F, Sautes-Fridman C and
Galon J: The immune contexture in human tumours: Impact on clinical
outcome. Nat Rev Cancer. 12:298–306. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Subrahmanyam PB, Dong Z, Gusenleitner D,
Giobbie-Hurder A, Severgnini M, Zhou J, Manos M, Eastman LM,
Maecker HT and Hodi FS: Distinct predictive biomarker candidates
for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma
patients. J Immunother Cancer. 6:182018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kaseb AO, Vence L, Blando J, Yadav SS,
Ikoma N, Pestana RC, Vauthey JN, Allison JP and Sharma P:
Immunologic correlates of pathologic complete response to
preoperative immunotherapy in hepatocellular carcinoma. Cancer
Immunol Res. 7:1390–1395. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Rosenberg SA, Spiess P and Lafreniere R: A
new approach to the adoptive immunotherapy of cancer with
tumor-infiltrating lymphocytes. Science. 233:1318–1321. 1986.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
He Y, Rozeboom L, Rivard CJ, Ellison K,
Dziadziuszko R, Yu H, Zhou C and Hirsch FR: PD-1, PD-L1 protein
expression in non-small cell lung cancer and their relationship
with tumor-infiltrating lymphocytes. Med Sci Monit. 23:1208–1216.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Teng MW, Ngiow SF, Ribas A and Smyth MJ:
Classifying cancers based on T-cell Infiltration and PD-L1. Cancer
Res. 75:2139–2145. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Park J, Kwon M, Kim KH, Kim TS, Hong SH,
Kim CG, Kang SG, Moon JH, Kim EH, Park SH, et al: Immune checkpoint
inhibitor-induced reinvigoration of tumor-infiltrating
CD8+ T cells is determined by their differentiation
status in glioblastoma. Clin Cancer Res. 25:2549–2559.
2019.PubMed/NCBI
|
|
23
|
Natarajan K, Jiang J, May NA, Mage MG,
Boyd LF, McShan AC, Sgourakis NG, Bax A and Margulies DH: The role
of molecular flexibility in antigen presentation and T cell
receptor-mediated signaling. Front Immunol. 9:16572018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Tokito T, Azuma K, Kawahara A, Ishii H,
Yamada K, Matsuo N, Kinoshita T, Mizukami N, Ono H, Kage M and
Hoshino T: Predictive relevance of PD-L1 expression combined with
CD8+ TIL density in stage III non-small cell lung cancer patients
receiving concurrent chemoradiotherapy. Eur J Cancer. 55:7–14.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
El-Guindy DM, Helal DS, Sabry NM and Abo
El-Nasr M: Programmed cell death ligand-1 (PD-L1) expression
combined with CD8 tumor infiltrating lymphocytes density in
non-small cell lung cancer patients. J Egypt Natl Canc Inst.
30:125–131. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kim SH, Go SI, Song DH, Park SW, Kim HR,
Jang I, Kim JD, Lee JS and Lee GW: Prognostic impact of CD8 and
programmed death-ligand 1 expression in patients with resectable
non-small cell lung cancer. Br J Cancer. 120:547–554. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lin G, Fan X, Zhu W, Huang C, Zhuang W, Xu
H, Lin X, Hu D, Huang Y, Jiang K, et al: Prognostic significance of
PD-L1 expression and tumor infiltrating lymphocyte in surgically
resectable non-small cell lung cancer. Oncotarget. 8:83986–83994.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Le DT, Uram JN, Wang H, Bartlett BR,
Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, et
al: PD-1 blockade in tumors with mismatch-repair deficiency. N Engl
J Med. 372:2509–2520. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Donnem T, Hald SM, Paulsen EE, Richardsen
E, Al-Saad S, Kilvaer TK, Brustugun OT, Helland A, Lund-Iversen M,
Poehl M, et al: Stromal CD8+ T-cell density-a promising
supplement to tnm staging in non-small cell lung cancer. Clin
Cancer Res. 21:2635–2643. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Al-Shibli KI, Donnem T, Al-Saad S, Persson
M, Bremnes RM and Busund LT: Prognostic effect of epithelial and
stromal lymphocyte infiltration in non-small cell lung cancer. Clin
Cancer Res. 14:5220–5227. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kawai O, Ishii G, Kubota K, Murata Y,
Naito Y, Mizuno T, Aokage K, Saijo N, Nishiwaki Y, Gemma A, et al:
Predominant infiltration of macrophages and CD8+ T cells
in cancer nests is a significant predictor of survival in stage IV
non-small cell lung cancer. Cancer. 113:1387–1395. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Sepesi B, Cuentes EP, Canales JR, Behrens
C, Correa A, Antonoff M, Gibbons DL, Heymach WH, Mehran R, Rice DC,
et al: Tumor-infiltrating lymphocytes and overall survival in
surgically resected tage II and III non-small cell lung cancer. Int
J Rad Oncology Biol Phys. 98:2232017. View Article : Google Scholar
|
|
33
|
Mazzaschi G, Madeddu D, Falco A,
Bocchialini G, Goldoni M, Sogni F, Armani G, Lagrasta CA, Lorusso
B, Mangiaracina C, et al: Low PD-1 expression in cytotoxic
CD8+ tumor-infiltrating lymphocytes confers an
immune-privileged tissue microenvironment in NSCLC with a
prognostic and predictive value. Clin Cancer Res. 24:407–419. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Bauml JM, Mick R, Ciunci C, Aggarwal C,
Davis C, Evans T, Deshpande C, Miller L, Patel P, Alley E, et al:
Pembrolizumab after completion of locally ablative therapy for
oligometastatic non-small cell lung cancer: A Phase 2 Trial. JAMA
Oncol. 5:1283–1280. 2019. View Article : Google Scholar
|
|
35
|
Nakazawa N, Yokobori T, Kaira K, Turtoi A,
Baatar S, Gombodorj N, Handa T, Tsukagoshi M, Ubukata Y, Kimura A,
et al: High stromal TGFBI in lung cancer and intratumoral
CD8-positive T cells were associated with poor prognosis and
therapeutic resistance to immune checkpoint inhibitors. Ann Surg
Oncol. 27:933–942. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kinoshita T, Kudo-Saito C, Muramatsu R,
Fujita T, Saito M, Nagumo H, Sakurai T, Noji S, Takahata E, Yaguchi
T, et al: Determination of poor prognostic immune features of
tumour microenvironment in non-smoking patients with lung
adenocarcinoma. Eur J Cancer. 86:15–27. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Koh J, Go H, Keam B, Kim MY, Nam SJ, Kim
TM, Lee SH, Min HS, Kim YT, Kim DW, et al: Clinicopathologic
analysis of programmed cell death-1 and programmed cell
death-ligand 1 and 2 expressions in pulmonary adenocarcinoma:
Comparison with histology and driver oncogenic alteration status.
Mod Pathol. 28:1154–1166. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zeng DQ, Yu YF, Ou QY, Li XY, Zhong RZ,
Xie CM and Hu QG: Prognostic and predictive value of
tumor-infiltrating lymphocytes for clinical therapeutic research in
patients with non-small cell lung cancer. Oncotarget.
7:13765–13781. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Hiraoka K, Miyamoto M, Cho Y, Suzuoki M,
Oshikiri T, Nakakubo Y, Itoh T, Ohbuchi T, Kondo S and Katoh H:
Concurrent infiltration by CD8+ T cells and
CD4+ T cells is a favourable prognostic factor in
non-small-cell lung carcinoma. Br J Cancer. 94:275–280. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Wakabayashi O, Yamazaki K, Oizumi S,
Hommura F, Kinoshita I, Ogura S, Dosaka-Akita H and Nishimura M:
CD4+ T cells in cancer stroma, not CD8+ T
cells in cancer cell nests, are associated with favorable prognosis
in human non-small cell lung cancers. Cancer Sci. 94:1003–1009.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Hu-Lieskovan S, Lisberg A, Zaretsky JM,
Grogan TR, Rizvi H, Wells DK, Carroll J, Cummings A, Madrigal J,
Jones B, et al: Tumor characteristics associated with benefit from
pembrolizumab in advanced non-small cell lung cancer. Clin Cancer
Res. 25:5061–5068. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Nishikawa H and Sakaguchi S: Regulatory T
cells in cancer immunotherapy. Curr Opin Immunol. 27:1–7. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Petersen RP, Campa MJ, Sperlazza J, Conlon
D, Joshi MB, Harpole DH Jr and Patz EF Jr: Tumor infiltrating
Foxp3+ regulatory T-cells are associated with recurrence
in pathologic stage I NSCLC patients. Cancer. 107:2866–2872. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Barua S, Fang P, Sharma A, Fujimoto J,
Wistuba I, Rao AUK and Lin SH: Spatial interaction of tumor cells
and regulatory T cells correlates with survival in non-small cell
lung cancer. Lung Cancer. 117:73–79. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Wu SP, Liao RQ, Tu HY, Wang WJ, Dong ZY,
Huang SM, Guo WB, Gou LY, Sun HW, Zhang Q, et al: Stromal
PD-L1-positive regulatory T cells and PD-1-positive CD8-positive T
cells define the response of different subsets of non-small cell
lung cancer to PD-1/PD-L1 blockade immunotherapy. J Thorac Oncol.
13:521–532. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Giatromanolaki A, Banham AH, Harris AL and
Koukourakis MI: FOXP3 infiltrating lymphocyte density and PD-L1
expression in operable non-small cell lung carcinoma. Exp Lung Res.
45:76–83. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Sakai K, Maeda S, Yamada Y, Chambers JK,
Uchida K, Nakayama H, Yonezawa T and Matsuki N: Association of
tumour-infiltrating regulatory T cells with adverse outcomes in
dogs with malignant tumours. Vet Comp Oncol. 16:330–336. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Jackute J, Zemaitis M, Pranys D,
Sitkauskiene B, Miliauskas S, Bajoriunas V, Lavinskiene S and
Sakalauskas R: The prognostic influence of tumor infiltrating
Foxp3+CD4+, CD4+ and
CD8+ T cells in resected non-small cell lung cancer. J
Inflamm (Lond). 12:632015. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Kinoshita F, Takada K, Yamada Y, Oku Y,
Kosai K, Ono Y, Tanaka K, Wakasu S, Oba T, Osoegawa A, et al:
Combined Evaluation of tumor-nfiltrating CD8 + and FoxP3 +
lymphocytes provides accurate prognosis in stage IA lung
adenocarcinoma. Ann Surg Oncol. 27:2102–2109. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
De Mattos-Arruda L, Cortes J, Santarpia L,
Vivancos A, Tabernero J, Reis-Filho JS and Seoane J: Circulating
tumour cells and cell-free DNA as tools for managing breast cancer.
Nat Rev Clin Oncol. 10:377–389. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Wang WJ, Tao Z, Gu W and Sun LH: Variation
of blood T lymphocyte subgroups in patients with non- small cell
lung cancer. Asian Pac J Cancer Prev. 14:4671–4673. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Xu L, Chen D, Lu C, Liu X, Wu G and Zhang
Y: Advanced lung cancer is associated with decreased expression of
perforin, CD95, CD38 by circulating CD3+CD8+ T lymphocytes. Ann
Clin Lab Sci. 45:528–532. 2015.PubMed/NCBI
|
|
53
|
Julia EP, Mando P, Rizzo MM, Cueto GR,
Tsou F, Luca R, Pupareli C, Bravo AI, Astorino W, Mordoh J, et al:
Peripheral changes in immune cell populations and soluble mediators
after anti-PD-1 therapy in non-small cell lung cancer and renal
cell carcinoma patients. Cancer Immunol Immunother. 68:1585–1596.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Ottonello S, Genova C, Cossu I, Fontana V,
Rijavec E, Rossi G, Biello F, Dal Bello MG, Tagliamento M, Alama A,
et al: Association between response to nivolumab treatment and
peripheral blood lymphocyte subsets in patients with non-small cell
lung cancer. Front Immunol. 11:1252020. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Inomata M, Kado T, Okazawa S, Imanishi S,
Taka C, Kambara K, Hirai T, Tanaka H, Tokui K, Hayashi K, et al:
Peripheral PD1-positive CD4 T-lymphocyte count can predict
progression-free survival in patients with non-small cell lung
cancer receiving immune checkpoint inhibitor. Anticancer Res.
39:6887–6893. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Thompson RH, Dong H, Lohse CM, Leibovich
BC, Blute ML, Cheville JC and Kwon ED: PD-1 is expressed by
tumor-infiltrating immune cells and is associated with poor outcome
for patients with renal cell carcinoma. Clin Cancer Res.
13:1757–1761. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Muenst S, Soysal SD, Gao F, Obermann EC,
Oertli D and Gillanders WE: The presence of programmed death 1
(PD-1)-positive tumor-infiltrating lymphocytes is associated with
poor prognosis in human breast cancer. Breast Cancer Res Treat.
139:667–676. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Hsu MC, Hsiao JR, Chang KC, Wu YH, Su IJ,
Jin YT and Chang Y: Increase of programmed death-1-expressing
intratumoral CD8 T cells predicts a poor prognosis for
nasopharyngeal carcinoma. Mod Pathol. 33:1393–1403. 2010.
View Article : Google Scholar
|
|
59
|
Mazzaschi G, Facchinetti F, Missale G,
Canetti D, Madeddu D, Zecca A, Veneziani M, Gelsomino F, Goldoni M,
Buti S, et al: The circulating pool of functionally competent NK
and CD8+ cells predicts the outcome of anti-PD1 treatment in
advanced NSCLC. Lung Cancer. 127:153–163. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Zhuo M, Chen H, Zhang T, Yang X, Zhong J,
Wang Y, An T, Wu M, Wang Z, Huang J and Zhao J: The potential
predictive value of circulating immune cell ratio and tumor marker
in atezolizumab treated advanced non-small cell lung cancer
patients. Cancer Biomark. 22:467–476. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Schenkel JM and Masopust D:
Tissue-resident memory T cells. Immunity. 41:886–897. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Kilvaer TK, Paulsen EE, Khanehkenari MR,
Al-Saad S, Johansen RM, Al-Shibli K, Bremnes RM, Busund LT and
Donnem T: The presence of intraepithelial CD45RO+ cells in resected
lymph nodes with metastases from NSCLC patients is an independent
predictor of disease-specific survival. Br J Cancer. 114:1145–1151.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Liu C, Hu Q, Xu B, Hu X, Su H, Li Q, Zhang
X, Yue J and Yu J: Peripheral memory and naïve T cells in non-small
cell lung cancer patients with lung metastases undergoing
stereotactic body radiotherapy: Predictors of early tumor response.
Cancer Cell Int. 19:1212019. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Manjarrez-Orduno N, Menard LC, Kansal S,
Fischer P, Kakrecha B, Jiang C, Cunningham M, Greenawalt D, Patel
V, Yang M, et al: Circulating T cell subpopulations correlate with
immune responses at the tumor site and clinical response to PD1
inhibition in non-small cell lung cancer. Front Immunol.
9:16132018. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Kunert A, Basak EA, Hurkmans DP, Balcioglu
HE, Klaver Y, van Brakel M, Oostvogels AAM, Lamers CHJ, Bins S,
Koolen SLW, et al: CD45RA+CCR7- CD8 T cells lacking co-stimulatory
receptors demonstrate enhanced frequency in peripheral blood of
NSCLC patients responding to nivolumab. J Immunother Cancer.
7:1492019. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Djenidi F, Adam J, Goubar A, Durgeau A,
Meurice G, de Montpréville V, Validire P, Besse B and Mami-Chouaib
F: CD8+CD103+ tumor-infiltrating lymphocytes
are tumor-specific tissue-resident memory T cells and a prognostic
factor for survival in lung cancer patients. J Immunol.
194:3475–3486. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Iatropoulos MJ and Williams GM:
Proliferation markers. Exp Toxicol Pathol. 48:175–181. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Osa A, Uenami T, Koyama S, Fujimoto K,
Okuzaki D, Takimoto T, Hirata H, Yano Y, Yokota S, Kinehara Y, et
al: Clinical implications of monitoring nivolumab immunokinetics in
non-small cell lung cancer patients. JCI Insight. 3:e591252018.
View Article : Google Scholar
|
|
69
|
Kim KH, Cho J, Ku BM, Koh J, Sun JM, Lee
SH, Ahn JS, Cheon J, Min YJ, Park SH, et al: The first-week
proliferative response of peripheral blood
PD-1+CD8+ T cells predicts the response to
Anti-PD-1 therapy in solid tumors. Clin Cancer Res. 25:2144–2154.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Huang AC, Postow MA, Orlowski RJ, Mick R,
Bengsch B, Manne S, Xu W, Harmon S, Giles JR, Wenz B, et al: T-cell
invigoration to tumour burden ratio associated with anti-PD-1
response. Nature. 545:60–65. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Kamphorst AO, Pillai RN, Yang S, Nasti TH,
Akondy RS, Wieland A, Sica GL, Yu K, Koenig L, Patel NT, et al:
Proliferation of PD-1+ CD8 T cells in peripheral blood after
PD-1-targeted therapy in lung cancer patients. Proc Natl Acad Sci
USA. 114:4993–4998. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Kuchroo VK, Umetsu DT, DeKruyff RH and
Freeman GJ: The TIM gene family: Emerging roles in immunity and
disease. Nat Rev Immunol. 3:454–462. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Limagne E, Richard C, Thibaudin M, Fumet
JD, Truntzer C, Lagrange A, Favier L, Coudert B and Ghiringhelli F:
Tim-3/galectin-9 pathway and mMDSC control primary and secondary
resistances to PD-1 blockade in lung cancer patients.
Oncoimmunology. 8:e15645052019. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Koyama S, Akbay EA, Li YY, Herter-Sprie
GS, Buczkowski KA, Richards WG, Gandhi L, Redig AJ, Rodig SJ,
Asahina H, et al: Adaptive resistance to therapeutic PD-1 blockade
is associated with upregulation of alternative immune checkpoints.
Nat Commun. 7:105012016. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Japp AS, Kursunel MA, Meier S, Mälzer JN,
Li X, Rahman NA, Jekabsons W, Krause H, Magheli A, Klopf C, et al:
Dysfunction of PSA-specific CD8+ T cells in prostate
cancer patients correlates with CD38 and Tim-3 expression. Cancer
Immunol Immunother. 64:1487–1494. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Su H, Xie H, Dai C, Ren Y, She Y, Xu L,
Chen D, Xie D, Zhang L, Jiang G and Chen C: Characterization of
TIM-3 expression and its prognostic value in patients with
surgically resected lung adenocarcinoma. Lung Cancer. 121:18–24.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Kuhns MS, Davis MM and Garcia KC:
Deconstructing the form and function of the TCR/CD3 complex.
Immunity. 24:133–139. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Postow MA, Manuel M, Wong P, Yuan J, Dong
Z, Liu C, Perez S, Tanneau I, Noel M, Courtier A, et al: Peripheral
T cell receptor diversity is associated with clinical outcomes
following ipilimumab treatment in metastatic melanoma. J Immunother
Cancer. 3:232015. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Liu YY, Yang QF, Yang JS, Cao RB, Liang
JY, Liu YT, Zeng YL, Chen S, Xia XF, Zhang K and Liu L:
Characteristics and prognostic significance of profiling the
peripheral blood T-cell receptor repertoire in patients with
advanced lung cancer. Int J Cancer. 145:1423–1431. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Ruggiero E, Nicolay JP, Fronza R, Arens A,
Paruzynski A, Nowrouzi A, Ürenden G, Lulay C, Schneider S, Goerdt
S, et al: High-resolution analysis of the human T-cell receptor
repertoire. Nat Commun. 6:80812015. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Han J, Duan J, Bai H, Wang Y, Wan R, Wang
X, Chen S, Tian Y, Wang D, Fei K, et al: TCR repertoire diversity
of peripheral PD-1+CD8+ T cells predicts
clinical outcomes after immunotherapy in patients with non-small
cell lung cancer. Cancer Immunol Res. 8:146–154. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Kaplansky G and Bongrand P: Cytokines and
chemokines. Cell Mol Biol (Noisy-le-grand). 74:569–574. 2001.
|
|
83
|
Qu Z, Sun F, Zhou J, Li L, Shapiro SD and
Xiao G: Interleukin-6 prevents the initiation but enhances the
progression of lung cancer. Cancer Res. 75:3209–3215. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Silva EM, Mariano VS, Pastrez PRA, Pinto
MC, Castro AG, Syrjanen KJ and Longatto-Filho A: High systemic IL-6
is associated with worse prognosis in patients with non-small cell
lung cancer. PLoS One. 12:e01811252017. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Pan B, Che D, Cao J, Shen J, Jin S, Zhou
Y, Liu F, Gu K, Man Y, Shang L and Yu Y: Interleukin-17 levels
correlate with poor prognosis and vascular endothelial growth
factor concentration in the serum of patients with non-small cell
lung cancer. Biomarkers. 20:232–239. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Sanmamed MF, Perez-Gracia JL, Schalper KA,
Fusco JP, Gonzalez A, Rodriguez-Ruiz ME, Oñate C, Perez G, Alfaro
C, Martín-Algarra S, et al: Changes in serum interleukin-8 (IL-8)
levels reflect and predict response to anti-PD-1 treatment in
melanoma and non-small-cell lung cancer patients. Ann Oncol.
28:1988–1995. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Seruga B, Zhang HB, Bernstein LJ and
Tannock IF: Cytokines and their relationship to the symptoms and
outcome of cancer. Nat Rev Cancer. 8:887–899. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Thomas DA and Massagué J: TGF-beta
directly targets cytotoxic T cell functions during tumor evasion of
immune surveillance. Cancer Cell. 8:369–380. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Higgs BW, Morehouse CA, Streicher K,
Brohawn PZ, Pilataxi F, Gupta A and Ranade K: Interferon gamma
messenger RNA Signature in tumor biopsies predicts outcomes in
patients with non-small cell lung carcinoma or urothelial cancer
treated with durvalumab. Clin Cancer Res. 24:3857–3866. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Fehrenbacher L, Spira A, Ballinger M,
Kowanetz M, Vansteenkiste J, Mazieres J, Park K, Smith D,
Artal-Cortes A, Lewanski C, et al: Atezolizumab versus docetaxel
for patients with previously treated non-small-cell lung cancer
(POPLAR): A multicentre, open-label, phase 2 randomised controlled
trial. Lancet. 387:1837–1846. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Karachaliou N, Gonzalez-Cao M, Crespo G,
Drozdowskyj A, Aldeguer E, Gimenez-Capitan A, Teixido C,
Molina-Vila MA, Viteri S, De Los Llanos Gil M, et al: Interferon
gamma, an important marker of response to immune checkpoint
blockade in non-small cell lung cancer and melanoma patients. Ther
Adv Med Oncol. 10:17588340177497482018. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Hirashima T, Kanai T, Suzuki H, Yoshida H,
Matsushita A, Kawasumi H, Samejima Y, Noda Y, Nasu S, Tanaka A, et
al: The Levels of Interferon-gamma release as a biomarker for
non-small-cell lung cancer patients receiving immune checkpoint
inhibitors. Anticancer Res. 39:6231–6240. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Boutsikou E, Domvri K, Hardavella G,
Tsiouda D, Zarogoulidis K and Kontakiotis T: Tumour necrosis
factor, interferon-gamma and interleukins as predictive markers of
antiprogrammed cell-death protein-1 treatment in advanced non-small
cell lung cancer: A pragmatic approach in clinical practice. Ther
Adv Med Oncol. 10:17588359187682382018. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Arrieta O, Montes-Servin E,
Hernandez-Martinez JM, Cardona AF, Casas-Ruiz E, Crispin JC, Motola
D, Flores-Estrada D and Barrera L: Expression of PD-1/PD-L1 and
PD-L2 in peripheral T-cells from non-small cell lung cancer
patients. Oncotarget. 8:101994–102005. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Patel SP and Kurzrock R: PD-L1 Expression
as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther.
14:847–856. 2015. View Article : Google Scholar : PubMed/NCBI
|
